Assembly Biosciences (NASDAQ:ASMB) Issues Earnings Results, Beats Expectations By $0.11 EPS

Assembly Biosciences (NASDAQ:ASMB) issued its earnings results on Thursday. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.11, Zacks reports. Assembly Biosciences had a negative net margin of 8.98% and a negative return on equity of 4.70%. The company had revenue of $8.21 million for the quarter, compared to analysts’ expectations of $9.27 million.

Assembly Biosciences Trading Down 3.8%

NASDAQ ASMB traded down $1.19 on Friday, hitting $29.74. 143,418 shares of the company’s stock traded hands, compared to its average volume of 141,040. The firm’s 50-day moving average price is $28.67 and its two-hundred day moving average price is $30.55. The firm has a market capitalization of $472.57 million, a PE ratio of -270.34 and a beta of 1.08. Assembly Biosciences has a 1-year low of $11.64 and a 1-year high of $39.71.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ASMB. Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a report on Monday, April 20th. Guggenheim lifted their price target on Assembly Biosciences from $39.00 to $43.00 and gave the company a “buy” rating in a report on Monday, April 6th. Wall Street Zen upgraded Assembly Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Sunday, March 29th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Assembly Biosciences in a research report on Monday. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $42.75.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE lifted its holdings in shares of Assembly Biosciences by 6,382.7% in the 3rd quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 3,319 shares during the period. Acadian Asset Management LLC lifted its holdings in Assembly Biosciences by 42.1% in the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock valued at $219,000 after acquiring an additional 6,823 shares during the period. Charles Schwab Investment Management Inc. purchased a new stake in Assembly Biosciences in the 4th quarter worth approximately $228,000. Virtus Investment Advisers LLC acquired a new stake in shares of Assembly Biosciences during the 4th quarter worth approximately $251,000. Finally, Qube Research & Technologies Ltd purchased a new position in shares of Assembly Biosciences during the 3rd quarter valued at approximately $282,000. 19.92% of the stock is currently owned by institutional investors and hedge funds.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.